Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-02-20
2008-12-16
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600, C514S049000, C514S050000, C514S085000, C514S086000, C514S247000, C514S256000, C435S183000, C435S191000
Reexamination Certificate
active
07465734
ABSTRACT:
This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or chemotherapy. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for treating a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.
REFERENCES:
patent: 3852266 (1974-12-01), Kiyanagi et al.
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4267171 (1981-05-01), Bergstrom et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4948882 (1990-08-01), Ruth
patent: 4963533 (1990-10-01), De Clercq et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5070082 (1991-12-01), Murdock et al.
patent: 5077282 (1991-12-01), Murdock et al.
patent: 5077283 (1991-12-01), Murdock et al.
patent: 5085983 (1992-02-01), Scanlon
patent: 5116822 (1992-05-01), De Clercq et al.
patent: 5116827 (1992-05-01), Murdock et al.
patent: 5212161 (1993-05-01), Moriniere et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5233031 (1993-08-01), Borch et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5274162 (1993-12-01), Glazier
patent: 5430148 (1995-07-01), Webber et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5521161 (1996-05-01), Malley et al.
patent: 5556942 (1996-09-01), Kauvar et al.
patent: 5616564 (1997-04-01), Rapaport et al.
patent: 5627165 (1997-05-01), Glazier
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5705336 (1998-01-01), Reed et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5968910 (1999-10-01), Balzarini
patent: 5981507 (1999-11-01), Josephson et al.
patent: 5998151 (1999-12-01), Johnston et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6339151 (2002-01-01), Shepard et al.
patent: 6495553 (2002-12-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 6677314 (2004-01-01), Klecker et al.
patent: 6677315 (2004-01-01), Klecker et al.
patent: 6682715 (2004-01-01), Klecker et al.
patent: 6683045 (2004-01-01), Klecker et al.
patent: 6683061 (2004-01-01), Shepard et al.
patent: 6703374 (2004-03-01), Klecker et al.
patent: 2001/0034440 (2001-10-01), Shepard et al.
patent: 2002/0022001 (2002-02-01), Klecker et al.
patent: 2002/0034473 (2002-03-01), Klecker et al.
patent: 2002/0119094 (2002-08-01), Klecker et al.
patent: 2002/0147175 (2002-10-01), Shepard et al.
patent: 2002/0151519 (2002-10-01), Shepard et al.
patent: 2002/0165199 (2002-11-01), Klecker et al.
patent: 2003/0049201 (2003-03-01), Klecker et al.
patent: 2003/0095921 (2003-05-01), Klecker et al.
patent: 32 29 169 (1984-02-01), None
patent: 32 29 169 (1984-09-01), None
patent: 0 095 294 (1983-11-01), None
patent: 0 283 065 (1988-09-01), None
patent: 982776 (1965-02-01), None
patent: 2003-133999 (2003-05-01), None
patent: WO 89/05817 (1989-06-01), None
patent: WO 90/03978 (1990-04-01), None
patent: WO 91/17474 (1991-11-01), None
patent: WO 92/20344 (1992-11-01), None
patent: WO 94/03467 (1994-02-01), None
patent: 94/11483 (1994-10-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 95/01806 (1995-01-01), None
patent: WO 95/08556 (1995-03-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO 96/07413 (1996-04-01), None
patent: WO 96/10030 (1996-04-01), None
patent: WO 96/23506 (1996-08-01), None
patent: WO 96/29336 (1996-09-01), None
patent: WO 96/33168 (1996-10-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 98/49177 (1998-11-01), None
patent: WO 99/06072 (1999-02-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 99/23104 (1999-05-01), None
patent: WO 99/37753 (1999-07-01), None
Collins, J.M. et al., “Suicide Prodrugs Activated by Thymidylate Synthase: Rationale for Treatment and Noninvasive Imaging of Tumors with Deoxyuridine Analogues”Clin. Cancer Res.5:1976-1981 (Aug. 1999).
Katki, A.G. et al., “Prodrugs Activated by Thymidylate Synthase: Treatment of Tumors with Deoxyuridine Analogs”Proc. Amer. Assoc. Cancer Res.39, Abstract No. 1275 (Mar. 1998).
Ayisi et al., “Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5′-monophosphate with adenine arabinoside-5′-monophosphate”Antiviral Res. 3:161-174 (1983).
Goldberg et al., “Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos”Am. J. Respir. Cell Mol. Biol. 17:265-271 (1997).
Pardo et al., “The incorporation of deoxyuridine monophosphate into DNA increases the sister-chromatid exchange yield”Exp. Cell Res. 168: 507-517 (1987).
Akdas, A. et al., “Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder”Eur. Urol. 29(4):483-486 (1996).
Almasan, A. et al., “Genetic instability as a consequence of inappropriate entry into and progression through S-phase”Cancer Metastasis Rev. 14:59-73 (1995).
Andersen et al., “Detection of c-erbb-2 related protein in sera from breast cancer patients”Acta Oncol. 34(4):499-504 (1995).
Antelman, D. et al., “Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein”Oncogene 10: 697-704 (1995).
Balzarini, J. et al., “Thymidylate synthase is the prinicipal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene”Mol. Pharmacol. 32:410-416 (1987).
Banerjee, D. et al., “Molecular mechanisms of resistance to antifolates, a review”Acta Biochem. Pol. 42(4):457-464 (1995).
Banerjee, D. et al., “Role of E2F-1 in chemosensitivity”Cancer Res. 58:4292-4296 (1998).
Barbour, K. W. et al., “A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2′-deoxyuridine in mammalian and bacterial cells”Mol. Pharmacol. 42:242-248 (1992).
Barr, P.J. et al., “Thymidylate synthetase-catalyzed conversions ofE-5-(2-Bromovinyl)-2′-deoxyuridylate”J. Biol. Chem.258(22):13627-13631 (1983).
Bergstrom, D. E. et al., “C-5-substituted pyrimidine nucleosides. 3. Reaction of allylic chlorides, alcohols, and acetates with pyrimidine nucleoside derived organopalladium intermediates”J. Org. Chem. 46(7):1432-1441 (1981).
Bertino, J. R. et al., “Resistance mechanisms to methotrexate in tumors”Stem Cells 14:5-9 (1996).
Bosslet, K. et al., “A novel one-step tumor-selective prodrug activation system”Tumor Targeting 1:45-50 (1995).
Bosslet, K. et al., “Elucidation of the mechanism enabling tumor selective prodrug monotherapy”Cancer Res. 58:1195-1201 (1998).
Brison, O., “Gene amplification and tumor progression”Biochem. Biophys. Acta 1155:25-41 (1993).
Carl, P.L. et al., “Protease-activated ‘prodrugs’ for cancer chemotherapy”PNAS USA 77(4):2224-2228 (1980).
Carreras, C.W. et al., “The catalytic mechanism and structure of thymidylate synthase”Ann. Rev. Biochem. 64:721-762 (1995).
Carter, P. et al., “Humanizatio
Celmed Oncology (USA), Inc.
Foley & Lardner LLP
Harris Alana M.
Konski, Esq. Antoinette F.
LandOfFree
Methods and compositions for overcoming resistance to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for overcoming resistance to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for overcoming resistance to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4047827